These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 10611634)

  • 1. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
    Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
    Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
    Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
    Gobert A; Lejeune F; Rivet JM; Audinot V; Newman-Tancredi A; Millan MJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1032-46. PubMed ID: 7791073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
    Gobert A; Di Cara B; Cistarelli L; Millan MJ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):338-46. PubMed ID: 12649387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
    Millan MJ; Gobert A; Rivet JM; Adhumeau-Auclair A; Cussac D; Newman-Tancredi A; Dekeyne A; Nicolas JP; Lejeune F
    Eur J Neurosci; 2000 Mar; 12(3):1079-95. PubMed ID: 10762339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
    Audinot V; Newman-Tancredi A; Cussac D; Millan MJ
    Neuropsychopharmacology; 2001 Sep; 25(3):410-22. PubMed ID: 11522469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.